Chronic Myeloid Leukemia

Mechanism Of Drug Resistance Demonstrated

Published in Blood Weekly, July 12th, 2001

A potent new cancer drug called STI-571, recently approved for sale by the U.S. Food and Drug Administration under the commercial name Gleevec^TM, has had remarkable success in treating patients with early-stage chronic myeloid leukemia (CML).

This drug continues to work well as an early-stage CML treatment. But, some clinical studies show that patients with advanced-stage CML initially respond to STI-571 and then suffer a relapse as the cancer becomes resistant to the drug.

Now, new research demonstrates exactly how this resistance develops, and may suggest ways to design even more effective drugs to treat CML.

CML is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-07-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry